The World Health Organizationhas just endorsed medicines that havenotpassed muster with western regulators.

There are always costs of both action and inaction; however, before a costly scheme is funded, better evidence of its effectiveness should be established.

The high persistence of substandard drugs and clinically inappropriate artemisinin monotherapies inAfrica risks patient safety and endangers the future of malaria treatment.

The proliferation of low-quality and counterfeit drugs is one of the most pressing problems in delivering life-saving medicines to the world's poorest patients.

Aid agencies, advocates, and national governments have a responsibility to ensurethatbillions of dollars inpharmaceutical procurementare spent on safe, effective, life-saving drugs.

Should countries should be switching from existing therapies of brand-name drugs to formulations made from knockoff drugs that are simpler for patients to take?

The Meltzer Commission makesrecommendations for reform of the International Monetary Fund, the World Bank, and the regional development banks.

Errorsin calculating the number of treated AIDS patients and the price of drugs ultimatelyresultinunsustainable programs andthe use of insufficiently tested drugs.